



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



GLPG2938

Item No. 34318

CAS Registry No.: 2130996-00-6
Formal Name: N-[2-ethoxy-6-(trifluoromethyl)-4-pyridinyl]-N'-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-3-pyridazinyl]methyl]-urea

MF: C₂₀H₁₉F₆N₇O₂

FW: 503.4


Purity: ≥98%

UV/Vis.: λ_{max}: 217 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GLPG2938 is supplied as a solid. A stock solution may be made by dissolving the GLPG2938 in the solvent of choice, which should be purged with an inert gas. GLPG2938 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of GLPG2938 in these solvents is approximately 1, 3, and 10 mg/ml, respectively.

Description

GLPG2938 is sphingosine-1-phosphate receptor 2 (S1P₂) antagonist.¹ It inhibits S1P-induced calcium flux in CHO cells overexpressing human S1P₂ (IC₅₀ = 8.8 nM). GLPG2938 inhibits S1P-induced IL-8 release in HFL1 cells (IC₅₀ = 0.6 nM) and S1P-induced contraction of human lung fibroblasts. *In vivo*, GLPG2938 (3, 10, and 30 mg/kg) prevents epithelial damage and pulmonary fibrosis, structural distortion, and inflammation in a mouse model of bleomycin-induced pulmonary fibrosis.

Reference

1. Mammoliti, O., Palisse, A., Joannesse, C., *et al.* Discovery of the S1P2 antagonist GLPG2938 (1-[2-ethoxy-6-(trifluoromethyl)-4-pyridinyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a preclinical candidate for the treatment of idiopathic pulmonary fibrosis. *J. Med. Chem.* **64**(9), 6037-6058 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/05/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM